32 results about "M2 Macrophage" patented technology

The invention discloses a high-activity injectable self-healing temperature-sensitive hydrogel dressing and a preparation method and application thereof, the high-activity injectable self-healing temperature-sensitive hydrogel dressing is obtained by forming a temperature-sensitive hydrogel through a two-dimensional nano material MXene aqueous solution and F127 under the hydrogen-bond interaction, combining an M2 macrophage source exosome on MXene under the electrostatic adsorption action, and wrapping the MXene through a network structure of the hydrogel. The preparation method is simple, an obtained sample is free of organic solution residues, reaction conditions are mild, operation is convenient, the raw material cost is low, the hydrogel dressing has temperature-sensitive, injectable and self-healing performance, the hydrogel dressing has temperature-sensitive and injectable performance, is sol at normal temperature, forms gel after making contact with skin and is convenient to smear and use on wounds, and experimental results prove that the hydrogel dressing has good application prospects. The hydrogel has good biocompatibility and relatively strong antibacterial performance, and can effectively play anti-inflammatory and vascular regeneration promoting roles in diabetic wounds and promote rapid repair of the diabetic wounds.

The invention discloses an immunomodulatory composition based on a cordycepin-selenium nano chelate and a preparation method thereof, and belongs to the technical field of biological medicines.The immunomodulatory composition is characterized in that 15-25 nm zero-valent selenium nano particles are chelated through hydroxyl of cordycepin and N7 site bidentate coordination, and a stable five-membered ring structure with the molar ratio is formed; the preparation method comprises the following steps: reducing sodium selenite in an inert atmosphere to generate selenium colloid, chelating the selenium colloid with a cordycepin ethanol solution, and carrying out ultrafiltration and freeze-drying to obtain the product. The invention aims to solve the problems of fuzzy structure, inconsistent batch, uncontrollable immunomodulatory function and the like caused by non-specific mixing in the prior art, and the composition can bidirectionally regulate and control IRF3 pathways, promote polarization of M2 type macrophages and proliferation of Treg cells, and has a clear immunomodulatory mechanism and excellent stability.

The present application relates to a kind of water gel support prepared by self-assembled polypeptide and the use of support obtained therefrom, the preparation method includes: 1) self-assembled peptide sequence is linked nerve growth factor analog peptide by covalent bond to obtain bonded functional polypeptide;2) macrophage is separated and cultured, and is induced to be " alternative activation " anti-inflammatory M2 macrophage, obtain culture supernatant and carry out filtration, obtain filtered cell culture supernatant;3) filtered cell culture supernatant is mixed with bonded functional polypeptide, obtain mixed solution and adjust the concentration of the mixed solution, the bonded functional polypeptide self-assembles and forms water gel support.The present application uses M2 macrophage condition culture supernatant to construct regenerative microenvironment, combines polypeptide functional water gel support, realizes better overall interaction, and prepares the water gel support that can supplement and regulate nerve regeneration, the support can promote nerve cell regeneration behavior, provides new selection for tissue engineering biomaterials.

This invention discloses a biomimetic nanocomposite, its preparation method, and its application in the preparation of products for treating atherosclerosis, belonging to the field of pharmaceutical preparation technology. The biomimetic nanocomposite is an Ir-TiO2 metal nanozyme encapsulated in an M2 macrophage membrane. This invention prepares a structurally biomimetic nanocomposite by coating Ir-TiO2 nanoparticles with an M2 macrophage membrane. After intravenous injection, the formed biomimetic nanocomposite actively targets endothelial cells in atherosclerotic lesions, releasing Ir-TiO2 antagonistically into the cytoplasm of plaque-containing endothelial cells and inflammatory macrophages. Once Ir-TiO2 reaches the lesion site, it exerts an enzymatic effect to achieve anti-inflammatory activity and promotes cholesterol excretion from inflammatory cells such as macrophages and smooth muscle cells at the lesion site, reducing intracellular lipid deposition, reducing foam cell formation, and promoting plaque growth. This nanotherapy can effectively prevent the progression of inflammation in atherosclerotic lesions and alleviate atherosclerosis.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

A nanoparticle for treating hepatocellular carcinoma (HCC) in which the nanoparticle includes a lipid phase and a core that contains one or more nucleic acids encoding a chimeric antigen receptor (CAR), a T-cell engager (TCE), and / or a therapeutic gene. The CAR and the TCE each binding specifically to an HCC tumor-associated antigen and the nanoparticle selectively delivers the one or more nucleic acids to M2 macrophages in vitro and in vivo. Also provided is a therapeutic composition that contains a plurality of the nanoparticle described above and a pharmaceutically acceptable excipient. Further provided are methods for converting HCC tumor-resident M2 macrophages into M1 macrophages, and for treating HCC.

The invention discloses a bionic nano drug delivery system for treating pterygium as well as a preparation method and application of the bionic nano drug delivery system. The bionic nano drug delivery system comprises an inner core and a bionic membrane shell, the inner core is composed of polylactic acid-glycolic acid copolymer nano-particles, and curcumin is encapsulated in the inner core to serve as a therapeutic drug; the biomimetic membrane shell is composed of an M2 type macrophage membrane and wraps the surfaces of the polylactic acid-glycolic acid copolymer nanoparticles. The drug-loading system can be administered in the form of eye drops, is used for treating pterygium, particularly shows a good treatment effect in a mouse corneal alkali burn model, and can promote polarization of macrophages to M2 type and regulate the ocular surface inflammation microenvironment. According to the invention, the biodegradability and slow release characteristics of PLGA, the anti-inflammatory activity of curcumin and the targeting and immunoregulation functions of M2 type macrophage membrane are combined, the stability and bioavailability of the medicine are remarkably improved, and an efficient and safe new strategy is provided for treatment of pterygium.

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.

The present application relates to the technical field of biological medicine, in particular to a new application of a BTK PROTAC compound NX-5948, especially to a new application of a Bruton's tyrosine kinase protein degradation targeting chimera BTK PROTAC compound NX-5948 in a drug for treating secondary hemophagocytic syndrome (HLH). In the present application, the BTK PROTAC compound NX-5948 inhibits the activation of the macrophage BTK / NF-κB axis signaling pathway through targeting, on the one hand, reduces the number of activated macrophages by inhibiting the proliferation and survival of macrophages, on the other hand, induces the polarization of macrophages from pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages through the immunoregulatory effect on macrophages, and then inhibits the release of cytokines and the occurrence and development of HLH, so that the effect of the new application of the present application is that it can inhibit the abnormal activation of macrophages and improve the clinical symptoms or laboratory indexes existing in patients with secondary hemophagocytic syndrome.

This invention belongs to the field of biomedical technology and provides the application of exosome-derived TRIM59 inhibitors in regulating macrophage M2 polarization and combating oral squamous cell carcinoma. The TRIM59 inhibitor uses exosomes derived from oral squamous cell carcinoma tissue as carriers, with the surface modified with the M2 macrophage-targeting molecule M2pep, internally loaded with TRIM59 inhibitors and KRT6B inhibitors, and loaded with STING pathway agonists. This invention relies on the microenvironment targeting and membrane surface targeting modification of tumor-derived exosomes to precisely deliver TRIM59 inhibitors and KRT6B inhibitors to M2 macrophages and tumor cells. By silencing TRIM59, the resistance of M2 macrophages to the STING pathway is relieved, forming a temporal synergistic effect of first unlocking and then activating with the STING agonist, driving macrophages to M1 polarization.

The invention provides an M2 macrophage exosome loaded canagliflozin nano-drug and application thereof, an M2 macrophage exosome is used as a carrier, and canagliflozin is loaded on the M2 macrophage exosome. The Exo-CANA delivery system is constructed for the first time, the exosomes are small in size, the phagocytosis of mononuclear macrophages can be effectively avoided, the exosomes can freely penetrate through vascular walls and extracellular matrixes, Th2 type airway inflammation, goblet cell metaplasia and pulmonary interstitial collagen deposition can be remarkably improved, and the treatment effect is remarkably superior to that of a CANA single-drug treatment group and an M2-Exos single-drug treatment group.

The invention belongs to the technical field of biological medicine, and particularly relates to an M2 macrophage membrane wrapped ROS response type bionic nano delivery system as well as a preparation method and application thereof. The ROS response type bionic nano delivery system wrapped by the M2 macrophage membrane is composed of ROS response nano particles carrying therapeutic drugs and the M2 macrophage membrane wrapping the ROS response nano particles. The ROS response type bionic nano delivery system wrapped by the M2 macrophage membrane provided by the invention is excellent in biocompatibility, has the functions of immune escape, precise targeting, removal of ROS in cells, inhibition of inflammatory injury and cell apoptosis and the like, and provides a bionic nano delivery system with targeting delivery, intelligent drug release and multi-dimensional regulation and control for atherosclerosis.

The present invention relates to a metal-organic framework for inhibiting the activity of M2 macrophages, and a pharmaceutical composition comprising same, wherein the metal-organic framework of the present invention is non-toxic to cells and can exhibit an effect of inhibiting the activity of M2 macrophages. More specifically, the metal-organic framework of the present invention can be provided as an anticancer composition for tumor-related macrophage-mediated diseases, particularly solid cancer, through the inhibition of M2 macrophages capable of increasing the expression of genes associated with parasite invasion, tissue remodeling, and tumor proliferation (immunomodulatory function), and can also be provided as a pharmaceutical composition for treating chronic infectious diseases, liver cirrhosis, obesity-related metabolic diseases, scar formation and idiopathic lung diseases.

The invention discloses co-delivery lipid nanoparticles targeting M2 type macrophages as well as a preparation method and application of the co-delivery lipid nanoparticles. The lipid nanoparticle is prepared from an ionizable cationic lipid, a neutral auxiliary lipid, cholesterol, a PEGylated lipid containing disulfide bonds, a PEGylated lipid of which the tail end is connected with mannose, and an encapsulated nucleic acid drug containing miR-99b and SIRP alpha siRNA, and glutathione responsive PEG exfoliation in a tumor microenvironment is realized by introducing DSPE-S-S-PEG3000; and DSPE-PEG2000-mannose is utilized to realize active targeting based on CD206 recognition, so that the therapeutic nucleic acid is co-delivered to the M2 type tumor-associated macrophages efficiently and specifically. The nanoparticles can synergistically reverse M2 macrophages into M1 anti-tumor phenotypes and block CD47-SIRP alpha'eating my 'signals, effectively remodel an immunosuppression microenvironment, and show excellent tumor targeting ability, tumor growth and metastasis inhibition and anti-tumor immune response promotion effects in hepatocellular carcinoma treatment.

The invention discloses a lysosome-oriented luteolin carbon dot as well as a preparation method and application thereof in the technical field of carbon dot application, luteolin and 2, 5-dihydroxyterephthalic acid are used as carbon source precursors, the luteolin carbon dot is prepared by a hydrothermal method, the particle size of the prepared luteolin carbon dot is 0.5-4 nm, and the particle size of the prepared luteolin carbon dot is 0.5-2 nm. The fluorescence excitation wavelength is 360 to 440 nm, the maximum emission wavelength is 540 nm, and the Zeta potential is-19 mv; researches find that luteolin carbon dots can guide macrophages and fat cell lysosomes, promote polarization of M2 type macrophages, and up-regulate heat production of beige fat cells and expression of a brown marker gene Ucp1; furthermore, the M2 type macrophage loaded with the luteolin carbon dots can promote expression of beige fat cells Ucp1 through carbon dot release and paracrine effects, so that heat production and energy consumption are increased, and a foundation is laid for development of intervention treatment schemes for obesity and related metabolic diseases based on the carbon dots in the future.

A nanoparticle for selective transfection of M2 macrophages, the nanoparticle including a lipid phase and a core that contains one or more nucleic acids. The nanoparticle selectively delivers the one or more nucleic acids to M2 macrophages in vitro and in vivo. Also provided is a therapeutic composition that contains a plurality of the nanoparticle described above and a pharmaceutically acceptable excipient. Further provided are methods for selective transfection of M2 macrophages, for converting M2 macrophages into M1 macrophages, and for treating a cancerous tumor. The methods are carried out by contacting M2 macrophages with a composition that includes a plurality of the nanoparticle mentioned above.

The invention relates to the field of biological medicines, discloses an application of icariside II in preparation of a medicine for treating pulmonary fibrosis, and further discloses a composition and a medicine for treating pulmonary fibrosis. It is verified for the first time that ISE II inhibits BLM-induced pulmonary fibrosis by regulating M2 macrophage exosome protein Hsp90aa1, the disease treatment field of ISE II is expanded, and the fundamental research depth of ISE II is increased; according to the application of the exosome derived from the M2 macrophages, the activation and migration of the fibroblasts are induced by the exosome derived from the M2 macrophages through an Hsp90aa1 / beta-catenin axis, related contents of interaction of the M2 macrophages and the fibroblasts in pulmonary fibrosis are supplemented, and a new research direction is developed for clinic; the specific component of the exosome cargo comprises Hsp90aa1 or other molecules, and can be used as a potential disease treatment target for subsequent research.

The invention discloses a triptolide-loaded engineered M2 macrophage exosome drug delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. A carrier of the delivery system is an M2 type macrophage source exosome combined and modified by phospholipid polyethylene glycol glucose; a loaded drug is triptolide, the triptolide is subjected to nano-micelle phospholipid polyethylene glycol glucose surface modification to form hypoxia response nanoparticles, M2Exo can target an inflammatory environment induced by macrophages, the specific anti-inflammatory biological function of M2Exo can be played, and the hypoxia response nanoparticles can be used for preparing the anti-inflammatory drug. Under the hypoxia condition, the compound is specifically taken by M1 macrophages, the polarization level and inflammatory response of the compound are inhibited, and the drug delivery efficiency is remarkably improved. Animal experiment model verification shows that the system can regulate and control rheumatoid arthritis synovial inflammation by regulating the polarization level of macrophages and improve the condition of arthropathy. According to the scheme, a new technical scheme is provided for precise treatment of inflammatory lesions such as rheumatoid arthritis caused by macrophages.

A method of treating cancer in a subject is provided, the method including administering to the subject a therapeutic amount of a composition including phosphatidylglycerol nanovesicles (NVs). A method of inhibiting M2 macrophage polarization in a tumor microenvironment by administering phosphatidylglycerol NVs is also provided, together with pharmaceutical compositions including phosphatidylglycerol NVs.

This invention provides siRNA that specifically binds to CD206 on M2 macrophages. The siRNA is at least one of siRNA-1, siRNA-2, and siRNA-3, or at least one of siRNA-4, siRNA-5, and siRNA-6. The siRNA provided by this invention specifically binds to CD206 on M2 macrophages, thereby reducing CD206 expression and promoting M2 macrophage proliferation, which in turn inhibits tumor cell proliferation and migration.

The invention belongs to the technical field of brain injury treatment medicines, and particularly relates to a brain injury targeting medicine as well as a preparation method and application thereof. The invention discloses a bionic delivery system for targeting ferroptosis and immune regulation, which is formed by mixing M2 macrophage exosome-lipidosome mixed nano-vesicles loaded with Fer-1 so as to solve challenges in traumatic brain injury treatment, especially the problems that a ferroptosis inhibitor is difficult to deliver effectively and immune cell targeting is insufficient. Therefore, secondary injury of traumatic brain injury is relieved. The targeted drug delivery system disclosed by the invention shows an excellent curative effect in treatment of traumatic brain injury by virtue of a unique mechanism of the targeted drug delivery system, so that a new breakthrough is brought to the field of brain targeted drug delivery, and an innovative solution is also provided for a treatment strategy of secondary injury of traumatic brain injury.

The invention aims to provide an acid response type rheumatoid arthritis targeted therapy nano preparation as well as a synthesis method and application thereof, and belongs to the technical field of preparation of nano biomedical materials. The preparation method comprises the following steps: synthesizing Zn / SiO nano-particles with a dandelion-shaped structure through an oil-water two-phase method, loading methotrexate by utilizing the large-aperture characteristic of the particles, and coating an M2 macrophage membrane on the outer layer to prepare the methotrexate-loaded Zn / SiO nano-particles. The nano preparation has good biocompatibility, stability and capability of targeting rheumatoid arthritis parts by virtue of inflammation chemotaxis and homologous targeting effects of M2 macrophage membranes. In an acidic microenvironment, the nanoparticles can respond to release zinc ions and drugs, so that safe and effective treatment of rheumatoid arthritis is realized.

This invention belongs to the fields of pharmaceutical formulation and biomedicine, and relates to an anti-atherosclerotic hybrid exosome, its preparation method, and its application. A hybrid composed of M2 macrophage exosomes and liposomes is used as a carrier, with the carrier loaded with a ferroptosis inhibitor and atorvastatin. The drug loading and encapsulation efficiency of the ferroptosis inhibitor are 1.55–2.57% and 11.99–49.86%, respectively; the drug loading and encapsulation efficiency of atorvastatin are 1.48–12.66% and 46.4–77.31%, respectively. The hybrid exosome provided by this invention has inflammatory targeting ability and higher stability, and can avoid the first-pass effect of the liver and the clearance of the circulatory system through intravenous injection. Simultaneously, this hybrid exosome has effects such as inhibiting ferroptosis, promoting cholesterol efflux, promoting cell burial, anti-inflammation, and regulating the immune microenvironment, enabling multi-faceted treatment of atherosclerosis, thus achieving better therapeutic effects.

The invention discloses a shell-core type micro-capsule material with mechanical stimulation sequential response and a preparation method. The shell-core type micro-capsule material is of a core-shell structure and is prepared by adopting a three-phase micro-fluidic method; the internal phase is vegetable oil, the external phase is fluorine oil, and the intermediate phase is a PEGDMA aqueous solution. The shell-core type micro-capsule material has good biocompatibility and chemical stability, so that the shell-core type micro-capsule material can still keep good mechanical properties in a complex environment of an articular cavity, a shell layer and an inner core can respectively carry water-soluble and fat-soluble drugs, and local mechanical stimulation response release is realized. The microcapsule releases the anti-inflammatory drug in the early stage of OA repair, promotes the M1 type macrophage to be converted into M2 type macrophage, and reduces the inflammatory mediator expression of the macrophage; the drug for promoting chondrocyte differentiation is released in the middle stage of OA repair, matrix remodeling is promoted, and OA cartilage healing is accelerated. The material has good application prospects in skeletal muscle system disease treatment and other aspects.

Described herein is method of treating and / or ameliorating a wound in a subject in need thereof. The method includes measuring an expression of a first and second panel of genes from a sample from the wound, wherein when at least one gene from the first panel is expressed, a pro-inflammatory agent is administered to the subject, and wherein when at least one gene from the second panel is expressed, an anti-inflammatory or M2 macrophage-promoting agent is administered to the subject, thus treating and / or ameliorating the wound in the subject.

The invention provides an application of PLAC8 as a detection target in preparation of a tumor diagnosis product, and relates to the technical field of biomedicine, the technical key points are as follows: the application of the PLAC8 as the detection target in preparation of the tumor diagnosis product and a tumor prognosis condition inspection product integrates three gallbladder cancer clinical queues, and has the advantages of high accuracy, high sensitivity and high reliability. By combining a cross-species model and technologies of multiple immunofluorescence, single cell RNA sequencing and the like, the PLAC8 is found to be a cross-species conservative M2 macrophage gene with significant difference. PLAC8 is abnormally enriched in gallbladder cancer tissues, and normal gallbladder epithelium is almost not expressed and can be stably detected through tumor tissues and peripheral blood. Expression of the gene is limited to a macrophage cluster, the gene is in positive correlation with M2 markers CD206 and CD163, and M2 polarization is promoted by regulating cholesterol metabolism. Clinical verifications show that increase of PLAC8 + CD163 + macrophages in tumors is an independent prognosis factor, high expression is closely related to short lifetime of patients and increase of chemotherapy non-response rate, and PLAC8 can be used as a potential biomarker for evaluating drug resistance of gallbladder cancer chemotherapy and tumor progression.

The invention relates to a nano-drug for dual-targeting M2 type macrophages as well as a preparation method and application of the nano-drug, and belongs to the technical field of biological medicines. The nano-drug for dual targeting of M2 type macrophages comprises USPIO, N-ADOBSA and CD163, the CD163 has the function of targeting M2 type macrophages, and the N-ADOBSA has the ability of targeting lysosome, so that the USPIO can act on the lysosome of M2 type macrophages in a targeting manner, the nano-drug is positioned to the lysosome, ferric iron in the USPIO is combined with a metabolic pathway of the lysosome, and the effect of targeting the M2 type macrophages is achieved. The ferroptosis process of the M2 macrophages is induced, so that the effects of targeting the M2 macrophages and reducing the activity of the M2 macrophages are realized, and the application significance in tumor treatment is important.

This application relates to the field of biomedical technology, specifically disclosing a siRNA lipid nanoparticle delivery system for treating lung infections, its preparation method, and its application. This application utilizes M2 macrophage-targeting lipid nanoparticles (LNPs) as carriers, delivering WTAP-targeting siRNA to alveolar macrophages via intratracheal instillation. This achieves specific intervention in the m6A methylation modification of alveolar macrophages, thereby actively enhancing the phagocytic clearance, inflammation regulation, and bactericidal functions of AMs, ultimately improving the host's defense against lung bacterial infections (especially drug-resistant bacterial infections).

The application belongs to the field of biological medicine, and particularly relates to a targeting CD47, M2 type macrophage affinity peptide. The CD47 affinity peptide has an amino acid sequence as shown in SEQ ID NO:1, and the M2 type macrophage targeting peptide has an amino acid sequence as shown in SEQ ID NO:2. The application also relates to preparation and application thereof, including constituting a double-targeting peptide and a transmembrane fusion protein; synthesizing the above molecules by nucleic acid molecule expression; and particularly designing a polypeptide expression and nano delivery system based on an engineered cell membrane. The molecules of the application can be affinity to CD47 and M2 type macrophage affinity peptides, and after designing a nano carrier combined with a STING agonist, the M2 type macrophage is reprogrammed, and the anti-tumor immune response is further enhanced.

This invention relates to the field of cardiovascular diseases and discloses the application of miRNA-454 in the treatment of atherosclerosis. This invention is the first to discover that hsa-miRNA-454-3p can bind to the 3'UTR region of IRF1 mRNA, inhibiting IRF1 expression, thereby suppressing the IRF1-NF-κB pathway and M1 macrophage polarization, promoting M2 macrophage polarization, and simultaneously restoring macrophage phagocytic capacity. This dual regulation reduces plaque inflammation, promotes the clearance of apoptotic debris from lesions, and ultimately slows down atherosclerosis.